3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Hematologic Neoplasms
2
Cholangiocarcinoma
2
Noonan Syndrome 6
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Granuloma, Plasma Cell
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma Of Esophagus
1
ALK-positive Non-small Cell Lung Cancer
1
Interventions
Rituximab
24
Cyclophosphamide
14
fludarabine
8
Etoposide
6
Vincristine
5
Prednisone
5
Doxorubicin
5
fludarabine phosphate
4
Carboplatin
4
venetoclax
3
obinutuzumab
3
ibrutinib
3
atezolizumab
3
Whole-Body Irradiation
3
Mycophenolic Acid
3
Lenalidomide
3
Ifosfamide
3
Cytarabine
3
Carmustine
3
Bortezomib
3
Bendamustine Hydrochloride
3
ublituximab
2
pembrolizumab
2
pegfilgrastim
2
ibritumomab tiuxetan
2
Tiragolumab
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Indium
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, B-Cell
×
ceritinib
×
Clear all
NCT02186821
2021-04-08
SIGNATURE
Novartis
Phase 2
Terminated
47 enrolled
13 charts